Moderna lowers full-year outlook; shares fall in premarket trading
Moderna shares fell more than 2% in premarket trading Friday after the biotechnology company reported second-quarter results and lowered some of its full-year financial forecasts. The vaccine maker reported earnings of $1.97 per share, below the $2.03-per-share expectation from analysts surveyed by FactSet. Quarterly revenue was $145 million, exceeding the consensus estimate of $102.9 million. Moderna also said it plans to reduce its 2026 drug research and development spending from its previous expectation. The company lowered its full-year R&D target to $2.9 billion, below its previous forecast of $3 billion and the market consensus of $2.93 billion.
Moderna shares fell more than 2% in premarket trading Friday after the biotechnology company reported second-quarter results and lowered some of its full-year financial forecasts.
The vaccine maker reported earnings of $1.97 per share, below the $2.03-per-share expectation from analysts surveyed by FactSet. Quarterly revenue was $145 million, exceeding the consensus estimate of $102.9 million.
Moderna also said it plans to reduce its 2026 drug research and development spending from its previous expectation. The company lowered its full-year R&D target to $2.9 billion, below its previous forecast of $3 billion and the market consensus of $2.93 billion.
The vaccine maker reported earnings of $1.97 per share, below the $2.03-per-share expectation from analysts surveyed by FactSet. Quarterly revenue was $145 million, exceeding the consensus estimate of $102.9 million.
Moderna also said it plans to reduce its 2026 drug research and development spending from its previous expectation. The company lowered its full-year R&D target to $2.9 billion, below its previous forecast of $3 billion and the market consensus of $2.93 billion.